Two men sentenced for leading a $17M Medicare fraud involving unnecessary genetic testing and falsified clinical laboratory enrollment. DOJ and HHS investigations highlight regulatory compliance risks.

FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.

Congress returns to negotiate FY 2026 government funding with a deadline on Sept 30, facing bipartisan challenges and potential shutdown.

A federal court blocks key provisions of the CMS Marketplace Integrity and Affordability rule affecting ACA exchanges, prompting an appeal from the Trump administration. Changes impact health plan design, enrollment rules, and taxpayer costs.

Healthcare policy and insurance coverage issues, including Medicaid cuts and ACA subsidy expirations, are central to the 2026 U.S. midterm elections amid regulatory challenges at CDC and HHS.

AMA urges HHS to retain the U.S. Preventive Services Task Force members amidst reports of planned dismissals, highlighting the panel's role in guiding evidence-based preventive care covered by insurers. Supreme Court upholds ACA's preventive coverage mandate.

The DOJ and HHS have reestablished the False Claims Act Working Group to heighten enforcement of healthcare fraud, focusing on Medicare, Medicaid, pricing, and EHR compliance risks.

The DOJ and HHS have established a joint False Claims Act Working Group to strengthen healthcare fraud investigations using advanced data analytics and interagency cooperation.

In July 2025, DOJ and HHS formed a joint Working Group to intensify False Claims Act enforcement, focusing on data-driven investigations and payment suspensions in healthcare fraud cases.

The DOJ and HHS reestablish the False Claims Act Working Group to enhance enforcement against healthcare fraud and abuse in federal programs, emphasizing compliance and whistleblower roles.